SCHEDULE: ARK Investment Management Files Schedule 13G Amendment

ARK Investment Management LLC and Catherine D. Wood have filed an Amendment No. 3 to their Schedule 13G, reporting beneficial ownership of 10x Genomics, Inc. Class A Common Stock.

Summary

• This filing is an Amendment No. 3 to a Schedule 13G, jointly filed by ARK Investment Management LLC ('ARK') and Catherine D. Wood.
• The filing pertains to the beneficial ownership of Class A Common Stock of 10x Genomics, Inc.
• ARK Investment Management LLC reports sole voting power over 9,343,840 shares and shared voting power over 122,999 shares.
• Catherine D. Wood reports shared voting power over 9,466,839 shares.
• Both ARK and Catherine D. Wood report shared dispositive power over 10,003,058 shares.
• The aggregate amount beneficially owned by each reporting person is 10,003,058 shares, representing 8.56% of the class.
• The date of the event requiring this filing is June 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding beneficial ownership reporting, with no new financial or strategic information.

Positives

• ARK Investment Management LLC and Catherine D. Wood are jointly reporting their beneficial ownership, indicating coordinated disclosure.
• The filing confirms a significant beneficial ownership stake of 8.56% in 10x Genomics, Inc.

Negatives

• No new financial performance data or strategic initiatives are disclosed in this filing.

Risks

• The filing does not explicitly mention any new risks. However, any investment in a company carries inherent market and operational risks.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding future performance.

Management Comments

• ARK Investment Management LLC and Catherine D. Wood agree to file Amendment No. 3 on Schedule 13G relating to their ownership of the Common Stock of the Issuer and that said Amendment No. 3 on Schedule 13G shall be filed on behalf of each of them.
• Kellen Carter, Chief Compliance Officer for ARK Investment Management LLC, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Catherine D. Wood, Chief Executive Officer and Chief Investment Officer, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

StockSavvy.ai notes that this filing is typical for large investment management firms like ARK, which actively manage and report on their significant equity holdings. The focus on 10x Genomics, a leader in single-cell and spatial genomics, aligns with ARK's known investment themes in disruptive innovation and life sciences.

Stakeholder Impact

• Shareholders: The filing provides transparency on significant ownership, which can influence market perception and trading activity.
• Management of 10x Genomics, Inc.: The reporting of substantial beneficial ownership by ARK and Catherine D. Wood may signal their ongoing interest and potential influence.

Next Steps

• Continued monitoring of ARK Investment Management LLC's and Catherine D. Wood's beneficial ownership in 10x Genomics, Inc.

Key Dates

Keywords

10x Genomics, ARK Investment Management, Catherine D. Wood, Schedule 13G, Beneficial Ownership, Class A Common Stock, Amendment